Supriya Lifescience Ltd

Supriya Lifescience Ltd has received an ESG rating of 'CRISIL ESG 65' in the 'Strong' category from CRISIL ESG Ratings & Analytics Limited. This voluntary rating signifies the company's commitment to environmental, social, and governance practices. The rating is a positive indicator for investors and stakeholders interested in sustainable business operations.

Supriya Lifescience Ltd has filed a petition before the Hon'ble Supreme Court of India on October 8, 2026. This action follows an earlier intimation to the Stock Exchanges on September 23, 2026, regarding an order received from the Hon'ble High Court. The company stated that the matter is currently sub judice and pending consideration by the Supreme Court. Consequently, Supriya Lifescience will not comment further on the merits or potential outcome of the proceedings at this stage. The company committed to closely monitoring the situation and informing stock exchanges and shareholders of any material developments or updates received from the Court, in accordance with applicable laws and regulations.

Supriya Lifescience Ltd has announced the closure of the trading window for its designated persons and their immediate relatives. This closure is effective from October 01, 2026, and will remain in effect until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading and ensuring fair market practices.

Supriya Lifescience Ltd has received a favorable order from the Hon'ble Court of Law for the provisional release of a 200 kg consignment of Ketamine Hydrochloride. The consignment, covered under Shipping Bill No. 3780061 dated June 2, 2026, will be released upon the company depositing ₹72 lakh with the Assistant Commissioner of Customs within one week. The court clarified that adjudication and criminal proceedings can continue as per law, and the concerned officer may follow procedures under Section 52A of the NDPS Act. The company is monitoring the situation and will provide further updates.

Supriya Lifescience Ltd has dispatched a letter to shareholders whose email IDs are not registered, providing a weblink to access the Annual Report for FY 2025-26 and the notice for the 18th Annual General Meeting (AGM). The AGM is scheduled for September 24, 2026, to be held via Video Conferencing. Shareholders are encouraged to register their email addresses with their Depository Participants for future electronic communications. The Annual Report and AGM notice are also available on the company's website and stock exchange websites.

Supriya Lifescience Ltd has provided an update on the judicial proceedings involving its General Manager – Sales & Marketing. The company reiterates that the matter remains sub judice and is awaiting adjudication. This status was previously communicated to investors through earnings calls and transcripts in August 2026. As of the current date, there have been no new developments or orders from the court. The company will continue to monitor the situation and will inform the stock exchanges of any material changes.

Supriya Lifescience Ltd. has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's corporate identity, operational data, employee statistics, and market presence. Key disclosures include its CIN, registered and corporate addresses, contact information, and the financial year covered (April 1, 2025, to March 31, 2026). The company's primary business activity is the manufacturing of Active Pharmaceutical Ingredients, accounting for 98.17% of its turnover. Supriya Lifescience serves a diversified customer base across 28 national and 128 international markets, with exports contributing 82% of its total turnover. The report also outlines employee demographics, including gender representation, and notes the absence of differently-abled employees and workers.

Supriya Lifescience Ltd has announced its 18th Annual General Meeting (AGM) will be held on Thursday, September 24, 2026, at 3:00 p.m. IST via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company will present the Audited Financial Statements for the financial year ended March 31, 2026, along with the Board and Auditors' reports. A final dividend of ₹1.00 per equity share (50%) for FY26 is proposed. Additionally, two directors retiring by rotation will seek re-appointment, and the remuneration of Cost Auditors for FY 2026-27 will be ratified. The Annual Report, including the Business Responsibility and Sustainability Report, is available on the company's website.

Supriya Lifescience Ltd has submitted its Annual Report for the financial year 2025-26, which includes the Business Responsibility and Sustainability Report. The report details the company's performance, strategic initiatives, and ESG commitments. The 18th Annual General Meeting (AGM) is scheduled for September 24, 2026, to be held via Video Conferencing. The report highlights the company's highest-ever revenue and EBITDA, driven by strong demand, favorable product mix, backward integration, and disciplined execution. Supriya Lifescience is focusing on API franchise enhancement, new product development, R&D capabilities, and expanding into formulations and specialized dosage forms. The Annual Report is available on the company's website.

Supriya Lifescience Ltd has announced the record date for determining eligibility for the final dividend for FY 2025-26. The Board of Directors recommended a dividend of Re. 1.00 per equity share, subject to member approval at the Annual General Meeting (AGM) scheduled for September 24, 2026. The record date is fixed as Friday, September 4, 2026. If approved, the dividend will be paid within 30 days to eligible shareholders.